(B) | 1. |
¤@55·³¤k©Ê³Ìªñªº¨Ò¦æ¨Å©ÐX¥úÄá¼vÀˬdµo²{¥ª°¼¨Å©Ð²§±`¶t¤Æ¡C¦¹¯f¤H¹L¥h¨Å骬ªp¨}¦n¡A¨ÃµL¨ä¥L¹L¥h¯f¥v¡A¦oªº«¼¶ý80·³¦]¨ÅÀù¦º¤`¡A§¹¾ãªº®a±Ú¥v¤¤¨ÃµL¨ä¥L®a±Ú¦¨û¿©±w¨ÅÀù©Î§Z±_Àù¡C²z¾ÇÀˬd(¥]¬A¨Å©Ð»PµÅ¤U²O¤Úµ²Àˬd)¨ÃµL²§±`µo²{¡A¦å²G¹³¡B¦å²M¥Í¤Æ¡B§¿²G»P¯Ý³¡¢æ¥úÄá¼vµ¥Àˬd§¡¥¿±`¡C¯f¤H±µ¨ü¢æ¥ú¼v¹³¾É¤Þ²Ê°w¤Á¤ùÀˬd¡A³ø§i¬°«Iŧ©Ê¨ÅºÞ¸¢¸¢Àù(invasive ductal adenocarcinoma)¡A¦o±µ¨ü¨Å©Ð²§±`¶t¤Æ¤Á°£¡A»P¥ª°¼µÅ¤U«eï²O¤Úµ²(sentinel lymph node) ¤Á°£±Ä¼Ë¡C ¯f²zÀˬd½T»{¤@Ó1.1¤½¤À¤j¤pªºinvasive ductal
adenocarcinoma¡A¤â³NÃä½t°®²b¨ÃµL¸~½F«I¥Ç¡A¥B«eï²O¤Úµ²§¡¨S¦³Àù²ÓMÂಾ«I¥Ç¡C¤U¦C³B¸m¡A¹ï¦¹¯f¤Hªº¥¼¨ÓªvÀøp¹º³Ì¦³À°§U¡H
|
A. | °l¥[¶i¦æ¥ª°¼µÅ¤U²O¤Úµ²¹ø²M¤â³N(radical lymph node dissection) |
B. | ¯f²z²Õ´¬V¦âER (estrogen±µ¨üÅé)»PPR (progesterone±µ¨üÅé)ªºªí²{±¡§Î |
C. | ¥þ¨ªº¥¿¤l±½´yÄá¼v(18-FDG-PET scan) |
D. | BRCA1¬ðÅܪº°ò¦]ÀË´ú |
E. | BRCA2¬ðÅܪº°ò¦]ÀË´ú |
|
(C) | 2. |
¤@70·³¨k©Ê¦³40 pack-yearªº©âµÒ¥v¡Aªñ¤TÓ¤ë©I§l«æ«P´c¤Æ¨Ó¨D¶E¡C¥L±q¨Æ©ó¥Ûºø(asbestos)¥Ë¤u¤H¦³ªñ40¦~¾·~¥v¡C¯Ý³¡X¥úµo²{¥k°¼¤j¶q¦Ø½¤¿n¤ô¡A¦Ø½¤¿n¤ô©â§lÀˬdµo²{mesothelioma²ÓM¡C¯ÝµÄ¹q¸£Â_¼h±½´yµo²{¤j½d³òÄjº©©Ê¥k°¼¦Ø½¤¼W«p¡AªÍªù»PÁa»JµÄ²O¤Úµ²¸~¤j¡A¦ý¨ÃµLªÍ¹ê½è¸~¶ô¡A¦Ø½¤¤Á¤ù¤]Ãҹꬰ¤W¥Ö²ÓM«¬(epithelial-type) mesothelioma¡C¥LªºªÍ¥\¯à¤£¨}¡Aforced vital capacity (FVC)¶È¦³1.5¤É¡C¤U¦C¦óªÌ¬°¹ï¦¹¯f¤H³Ì«ê·íªºªvÀø¿ï¶µ¡H
|
A. | ¤â³N¸~½F¤Á°£extrapleural pneumonectomy¡A±µµÛµ¹¤©»²§U©Êcisplatin/ pemetrexed¤ÆÀø»P¯ÝµÄ©ñ®gªvÀø |
B. | ¥ýµ¹¤©neoadjuvant·s»²§U©Êcisplatin/ pemetrexed¤ÆÀø»P¯ÝµÄ©ñ®gªvÀø¡A¦A±µ¨ü¤â³N¸~½F¤Á°£ |
C. | ±µ¨ücisplatin/ pemetrexed²Õ¦X¦¡¤Æ¾ÇªvÀø |
D. | ±µ¨ücisplatin/ pemetrexed²Õ¦X¦¡¤ÆÀø¡A¨Ö¥Î¯ÝµÄ©ñ®gªvÀø |
E. | ±µ¨ü¯ÝµÄ©ñ®gªvÀø |
|
(C) | 3. |
·í¨Ï¥Î¤W¥Ö¥Íªø¦]¤l±µ¨üÅéEGFR³æ®è§ÜÅé(cetuximab©Îpanitumumab monoclonal antibody)§@¬°¥Íª«©Êªv¾¯¨ÓªvÀøÂಾ©Êµ²ª½¸zÀù¡A¸Ó³æ®è§ÜÅ馳ª½±µ§Ü¸~½F¼W¥Í®ÄªG(direct anti-proliferative effect)¡C¤U¦C¦óºØ¹êÅç«ÇÀË´ú¤wª¾¥i¥Î©ó¹w´úªvÀø¤ÏÀ³¡H¦¹¹êÅç«ÇÀË´ú¥iµø¬°¹w´ú©Êªº¥Íª«¼Ð°O(predictive biomarker)¡C
|
A. | Treg levels |
B. | ¦å²MIL-10 levels |
C. | KRAS¬ðÅÜ |
D. | ¸~½FCD52 |
E. | EGFR¬ðÅÜ |
|
(C) | 4. |
¤@47·³¨k©Ê¦]¥k°¼ÀV³¡¸~¶ô¦³2Ó¤ë¦Ó¨Ó¨D¶E¡A²Ó°w¬ï¨ëÀˬdµo²{Å쪬¤W¥Ö²ÓMÀù(squamous cell carcinoma)¡AÀYÀV³¡¹q¸£Â_¼hÀˬdµo²{¥k°¼tonsil¤£¹ïºÙ¸~¶ô¡A¦X¨Ö¦³¥k°¼ÀV³¡²O¤Úµ²¸~¤j(level 2»Plevel 3)¡A¥L±µ¨ü¥k°¼tonsillectomy¤â³N¤Á°£»P¥kÀV¿ï¾Ü©Ê²O¤Úµ²¹ø²M³N(selective neck dissection)¡C¯f²z³ø§iÅã¥Ü¥k°¼tonsil¬°¤j¤p3.5¤½¤Àªºsquamous cell carcinoma¡A²`³¡¤â³NÃä½t¶È¤£¨ì1mm¡A¦P°¼¦hÓ²O¤Úµ²¤w«I¥Ç¡A¥B¤w¦³²O¤Úµ²²ó½¤¥~«I¥Ç(capsular
invasion)¡A¨Ã¥¼¨£¯«¸g©P³ò©Î¦åºÞ¤º«I¥Ç¡C¿Ã¥úì¦ìÂø¦Xªk(FISH)Àˬdµo²{¤HÃþ¨ÅÀY¯f¬r(HPV)²Ä16«¬¶§©Ê¡C¤U¦C¶i¤@¨BªvÀøpµe¦óªÌ³Ì¬°¦X¾A¡H
|
A. | ¦]HPV¶§©Ê¡A¹w«á¨}¦n¡AµL»Ý¶i¤@¨BªvÀø |
B. | ¹ïìµo³¡¦ì¦A¦¸¤â³N(re-resection)¡A¥H¹F¨ì¸û¥R¨¬©Î¼e¼sªº³±©Ê¤â³NÃä½t(negative margin) |
C. | »²§U©Ê(adjuvant) cisplatin¤Æ¾ÇªvÀø¦P¨B¨Ö¥Î°w¹ïìµo³¡¦ì»P¦P°¼ÀV³¡¤§©ñ®gÀøªk |
D. | °w¹ïìµo³¡¦ì»P¦P°¼ÀV³¡¡Aµ¹¤©»²§U©Ê©ñ®gÀøªk70Gy |
E. | °w¹ï¦P°¼ÀV³¡¡Aµ¹¤©»²§U©Ê©ñ®gÀøªk70Gy |
|
(D) | 5. |
¤@75·³¨k©Ê¿©±wÄáÅ@¸¢Àù¦X¨Ö°©ÀfÂಾ»P¯kµh¡C¦å¬õ¯ÀÀˬd¬°10.5 g/dL¡A§Ü²üº¸»XªvÀø«eªºPSA¬°1860 ng/mL¡C¥L±µ¨ü¨k©Ê²üº¸»Xç°£ªvÀø(androgen ablation)¡A¨Ï¥Îgoserelin(ªø®Ä«¬gonadotropin releasing hormone, GnRH, analog)¨Ö¥Îbicalutamide(§Ü¨k©Ê²üº¸»Xantiandrogen»s¾¯)¡A6Ó¤ë«á¡A¯kµh¯gª¬¤wÅãµÛ½w¸Ñ¡A¥BPSA¼ÆȤw°¦Ü0.1 ng/mL¡A¯f¤H«ùÄòªvÀø¥B¨C3Ó¤ëÀË´úPSA¡C¦ÜªvÀø18Ó¤ë®É¡APSA¬ðµM¤W¤É¦Ü15 ng/mL¡A«´úPSA½T»{¤W¤É¦Ü20 ng/mL¡A¦ý¨ä¥LÁ{§É»P©â¦å«ü¼Ð¨ÃµLÅܤơA¸A©Tà¬(testosterone)¼ÆȤ´¦³®Ä¨ü¨ì§í¨îat castrated
level¡CÂå®v³Ìªñ¤w¶}©l¨Ï¥ÎÂùÁC»ÄÆQbisphosphonateªvÀø¡Aºò±µ¤U¤@¨B§A«Øij±Ä¥Î¦óºØªvÀøµ¦²¤¡H
|
A. | §ó´«¥t¤@ºØ§Ü¨k©Ê²üº¸»Xªv¾¯antiandrogen |
B. | ¨Ï¥Îketoconazole¨Ö¥Îhydrocortisone |
C. | §ó´«¥t¤@ºØÂùÁC»ÄÆQbisphosphonateªv¾¯ |
D. | ¥ý°±¥Îbicalutamide¡A¦ýÄ~Äò¥ÎgoserelinªvÀø |
E. | ¥ý¥ÎStronium-89©ñ®g¦P¦ì¯ÀªvÀø |
|
(C) | 6. |
¤@47·³¤k©Ê¦]©Ê¦æ¬°«á(post-coital)¥X¦å¦Ó¨D¶E¡A°©¬ÖµÄÀˬd¥i¨£¤l®cÀV¦³¤@¢µ¤½¤À¸~¶ô¡A¤Á¤ùÃҹꬰÅ쪬¤W¥Ö²ÓMÀù(squamous cell carcinoma)¡A¶i¤@¨B°©¬ÖµÄÀˬdÃÒ¹ê¸~½F¤w½T©w½¯©µ«I¥Ç¦Ü¥ª°©¬ÖµÄ°¼¾À(side wall)¡A¹q¸£Â_¼hCT±½´y¨ÃµL»·¹j¾¹©xÂಾ¡C¥H¤UªvÀøpµe¦óªÌ³Ì¬°¾A·í¡H
|
A. | ®Ú°£©Ê¤l®c¤Á°£³Nradical hysterectomy¡A³N«áµ¹¤©°©¬Ö¤j½d³ò©ñ®gªvÀø¨Ö¥Î¦P¨Bcisplatin¤Æ¾ÇªvÀø |
B. | ¥ýµ¹¤©°©¬ÖµÄ©ñ®gªvÀø¡A¤§«á¶i¦æpaclitaxel¥[carboplatin¤Æ¾ÇªvÀø |
C. | °©¬ÖµÄ¤j½d³ò©ñ®gªvÀø¨Ö¥Î¦P¨Bcisplatin¬°¥Dªº¤Æ¾ÇªvÀø |
D. | ¥u¹ï¤l®cÀV¥X¦å³¡¦ìµ¹¤©§½³¡ªvÀø¡A¨Ãµ¹¤©¨ä¥L¤ä«ù©Ê¯gª¬Àøªk |
E. | ®Ú°£©Ê¤l®c¤Á°£³Nradical hysterectomy |
|
(B) | 7. |
¤@40·³¥xÆW¤k©Ê¯f¤H¡A¨ÃµL©âµÒ¥v¡A³Ìªñ³Q¶EÂ_¿©±w²ÄIV´ÁÂಾ©ÊªÍ¸¢Àù(adenocarcinoma)¡A¸~½Fªº°ò¦]ÀË´úµo²{¦³¤W¥Ö¥Íªø¦]¤l±µ¨üÅéEGFR²Ä21¥~Âà¤l(exon 21)¬ðÅÜ¡C½Ð°Ý¤U¦C¦óºØªvÀø³Ì¬°¾A·í¡H
|
A. | Gefitinib¨Ö¥ÎChemotherapy |
B. | Gefitinib |
C. | Bevacizumab |
D. | Gefitinib¨Ö¥ÎBevacizumab |
E. | Cetuximab |
|
(B) | 8. |
¤@45·³¨k©Ê¦]±Æ«K¤¤±a¦å»P¸Ñ«K«áùØ«æ«á«·P(tenesmus)¨Ó¨D¶E¡A¥D¶DÅãµÛ¸¡µÈ·P»P±Æ«K§xÃø¤w¦³¤@Ӥ륪¥k¡C¤j¸z¤ºµøÃè¥i¨£anal verge¤W¤è4¤½¤À¦³¤j«¬¸~¶ô¡A¥B¤ºµøÃè¤w¸gÃø¥H³q¹L¡A¤Á¤ùÃҹꬰadenocarcinoma¡C¹q¸£Â_¼h±½´yµo²{¦³¶W¹L10Ó¥H¤Wªº¨xÂಾ¸~¶ô¡A¥B¦û¾Ú¤F¤j½d³ò¨xŦ¡A¦å²MAST¡BALT¡BALP§¡¤W¤É¬ù¥¿±`¤Wªº3¿¡C«Øij¦óºØªvÀø³B¸m³Ì¬°¾A·í¡H
|
A. | ª½±µ¶}©l¤ÆÀøoxaliplatin¡B5FU¡Bleucovorin |
B. | ¥ý¬I¦æµ²¸z³y¤f³Ndiverting colostomy¡A¦A¶i¦æ²Õ¦X¦¡½Æ¤è¤Æ¾ÇªvÀø |
C. | ¥ý¶i¦æ¸~½F¤Á°£¤â³Nabdominoperineal resection (APR)¡A¦A¶i¦æ¤Æ¾ÇªvÀø |
D. | ¥ý¶i¦æ5FU¦P¨B¤ÆÀø©ñ®gÀøªk¡A¦A¶i¦æ¤Æ¾ÇªvÀøirinotecan¡B5FU¡Bleucovorin |
E. | ¶i¦æ¸~½F¤Á°£¤â³Nabdominoperineal resection (APR) |
|
(C) | 9. |
¦³Ãö¹¹DÀù¤§¦P¨B©ñÀø¤ÆÀø¡]concurrent chemoradiotherapy¡^¡A¤U¦C±Ôz¦óªÌ¬°¯u¡H1. ¨Ï¥Î5FU»Pcisplatin¨Ö¥Î©ñ®gÀøªk¡A¤jP¥i¹F¯f²z§¹¥þ½w¸Ñ²v(pathologic complete response¡^¬ù15-30%¡C
2. ¥Hpaclitaxel©Îirinotecan¬°¥Dªº¤ÆÀø¨Ö¥Î©ñ®gÀøªk¡A¥H½w¸Ñ²v»P¦s¬¡´Á¦Ó¨¥¡Aµ²ªGÀu©ó5FU»Pcisplatin¨Ö¥Î©ñ®gÀøªk¡C3.¥Hpaclitaxel¬°¥Dªº¤ÆÀø¨Ö¥Î©ñ®gÀøªk¡AG¸z¹Dªº¬ÛÃö¬r©Ê§C©ó5FU»Pcisplatin¨Ö¥Î©ñ®gÀøªk¡C4.©Ò¦³¯f¤H¦b±µ¨ü¦P¨B©ñÀø¤ÆÀø«e¡A§¡»Ý¸m©ñG¸zÁý¹ºÞ(»óGºÞ¡BG³y¤f¡BªÅ¸z³y¤fµ¥)¡C
(½Ð¿ï¥X©Ò¦³¥¿½Tµª®×)
|
A. | ±Ôz2»P3¬°¯u |
B. | ±Ôz1»P4¬°¯u |
C. | ±Ôz1»P3¬°¯u |
D. | ±Ôz1¡B2¡B3¡B4§¡¬°¯u |
E. | ¥H¤W¬Ò«D |
|
(D) | 10. |
¦³Ãö¯ØŦ¸¢Àù¡]adenocarcinoma of pancreas¡^¡A¦b±µ¨üªvÀø¥Ø¼Ð¬°®Úªv©Ê¡]curative¡^¤â³N¤Á°£pancreaticoduodenectomy¤§«á¡A¤U¦C±Ôz¦óªÌ¬°¯u¡H
|
A. | ¤´¦³¬ù50%¥H¤W¯f¤H·|¦³§½³¡°Ï°ì©Ê´_µo |
B. | ¯ØŦ¸¢Àù³æ¥Hpancreaticoduodenectomy¤â³N¤Á°£«á°lÂÜ¡A5¦~¾ãÅé¦s¬¡²v¤´¶È¬ù15-20%©Î§ó§C |
C. | ¤â³N«á¥Dn¥HÂಾ¦Ü¸¡½¤»P¨xŦ¬°¥D¡A§½³¡´_µo¤Ö¨£ |
D. | A»PB¬°¯u |
E. | B»PC¬°¯u |
|